3rd Annual Pharma Market Access and Pricing Summit Asia

Day 1 : Wed, 25 Sept 2019

Registration Starts & Morning Coffee

IBC Opening Address

Chairperson’s Opening Remarks


Pharma Transformation Keynote Address
Closing the Digital Divide Between Pharma and The Patient: How is Digital Technology Enabling Patient-Centricity?

Ron Kamienchick, Senior Director, Digital Health, Head of Diagnostics and Personalized Medicine, Teva Pharmaceuticals, United States

Pharma Leadership Roundtable:
The Next Pharma Industry Priorities: Business, Technology, Regulatory Compliance and Leadership

  • Pharma landscape and evolving regulations
  • Revolutionising the pharma industry towards patient engagement
  • Capturing new revenue streams and markets
  • Leveraging on strategic partnerships and collaborations to drive growth
  • The shift towards value-based pricing
  • Embracing digital transformation – Challenges and opportunities in Asia

Ryan Li, Head of Commercial Innovation & Alliance, Market Access, MSD, China
Angela Deluca, Head of Project Planning & Innovation Department, Japan Development, AbbVie, Japan

Aung Myo, Vice President of Clinical Development & Medical Affairs, Tessa Therapeutics, Singapore
Sophia Huang, Head of Regulatory Submission Management & Planning Beijing, Bayer Healthcare Company Limited, China
Amitabh Mishra, President & Chief Technology Officer, Emcure Pharma, India

Morning Networking & Refreshment Break

Market Access and Pricing Commences
New Market Access Strategies

Chairperson’s Opening Remarks

Improving Access to Medicine  

  • Global landscape of new therapeutics markets and trends
  • Country-Government partnerships for global health
  • Access acceleration strategies to the masses
  • On the road medicine delivery and its impacts

Collaborations and active partnerships for improved access in Greater China

  • Strategies to accelerate market access through online hospitals
  • Evaluation of innovative AI companies for partnerships

Ryan Li, Head of Commercial Innovation & Alliance, Market Access, MSD, China

Your A to Z guide to pricing in Japan [Part 1] Innovation needs innovation

  • An overview of the current drug price setting process in Japan including the limitations
  • A discussion on the potential for a new pricing process to meet the needs of new treatments, and what this may look like
  • A review of the regulatory pathways that have the potential to impact drug price in Japan

Neal Somchand, Principal, Deallus Consulting, Japan

Networking Lunch

Driving Market Access, a view from the Medical devices industry

  • How Medtronic looks at market access, building pathways to standards of care
  • Value based healthcare, risk sharing collaborations and business models
  • The rise of healthtech and their role in driving market access and UHC

Cristan Yang, Country Director, Medtronic, Philippines

Insurance-Pharma Partnership Considerations

  • Insurance sector outlook and impacts
  • Risks and opportunities for Pharma
  • Region potential and benefits to drive market access

Thalia Georgiou, Managing Partner, Healthcare Advisory Asia Pacific, Asia Care Group, Hong Kong

BMS’s Full Stakeholder Engagement Strategy

  • Integrating relevant stakeholders into the process
  • Challenges and benefits of the strategy

Christine Kuan, Market Access and External Affairs Director, Taiwan and South East Asia, Bristol-Myers Squibb, Taiwan

Afternoon Networking & Refreshment Break

 Digital Disruption, RWE and HEOR

South Korea Case Study: Regulatory Landscape and Market Access Trends

  • Korea’s current government policies and regulations
  • Updates on Risk-sharing agreements system
  • Digitalisation of healthcare sector and impacts on market access
  • Move towards patient centric healthcare

Jung Sungwon, Government Affairs and Market Director, Baxter, Korea

Digital Disruption, Data and Impact on Market Access Decision

Anh Bourcet, Director, ASPAC Health Economics & Market Access, Health Outcomes, Global Orthopedics & Biosurgery, Johnson & Johnson, Singapore

Chairperson’s Summary and End of Main Conference Day One

Day 2 : Thu, 26 Sept 2019

Pricing Models and Reimbursement Strategies

Morning Coffee

Chairperson’s Opening Remarks

Managing Price Regulation and Cost Containment

Robert Tan, Market Lead Access Asia, Vifor Pharma, Singapore

Panel Discussion:
How Would Pricing Strategies Help Manage Increasing Costs?

  • An open discussion on what strategy works best in Asia under different regulations
  • Expediting access to high-priced drugs in emerging markets whilst managing costs
  • Meeting the rising demand in Asia – Managing costs against reimbursement
  • Measures to manage costs in rare diseases and oncology space
  • Achieving price stability- challenges and opportunities
  • Addressing rising cost trends in therapeutics

Teresa Dioko, Head of Market Access and Public Affairs, Novo Nordisk, Philippines
Jun Feng, Market Access Associate Director, Asia, Abbvie, Singapore
Robert Tan, Market Lead Access Asia, Vifor Pharma, Singapore
Priya Narayan Matzen, Director APAC, Strategic Pricing and Policy, Janssen, Singapore
More panellists to be confirmed

Morning Networking and Refreshment Break

Your A to Z guide to pricing in Japan [Part 2] A cut above the rest: Is Japan going too far?

  • An overview of all the price adjustment rules currently in place in Japan
  • A review of Japan’s most recent price control measure – the HTA system, together with the recent changes of the price maintenance premium
  • A discussion around what the future price adjustment landscape may look like

Yuki Sato, Representative Director, Deallus Consulting, Japan

Comparison of Regional Pricing Strategies

  • Highlights in key markets: Japan, China, Singapore
  • Challenges and benefits of respective pricing models
  • Vietnam: Improving accessibility and changing reimbursement landscape

Priya Narayan Matzen, Director APAC, Strategic Pricing and Policy, Janssen, Singapore

Networking Lunch

Pricing Regulation Analysis in Asia: Case Study of Philippines

  • Market access considerations in a UHC environment
  • Regional price regulation analysis

Teresa Dioko, Head of Market Access and Public Affairs, Novo Nordisk, Philippines

Market Segments in Focus

*Topic to be confirmed*

Sittipong Liamsuwan, Policy and Access Director, MSD, Thailand

China Case Study:
Henlius’ Biosimilars Market Entry

  • Potential of biosimilars in China
  • Market access challenges and regulatory requirements
  • Henlius’ approach to improve biosimilars uptake

Jeremy Chien, Marketing Director, Shanghai Henlius, China

Afternoon Networking & Refreshment Break

Insurance Co-payment and Reimbursement Models for Value based Healthcare in Asia

Contact ShiHui.Wong@ibcasia.com.sg for speaking opportunities

Market Access from Prescriber’s Perspective: Use of medicines for heart failures

Dorren Su-Yin Tan, Assistant Director, CorpDev, Yishun Health, Singapore

Chairperson’s Summary and End of Main Conference